ES2186340T3 - Utilizacion de polipeptidos fgf-5 para la prevencion de la muerte de neuronas retinales y para el tratamiento de enfermedades oculares. - Google Patents

Utilizacion de polipeptidos fgf-5 para la prevencion de la muerte de neuronas retinales y para el tratamiento de enfermedades oculares.

Info

Publication number
ES2186340T3
ES2186340T3 ES99912439T ES99912439T ES2186340T3 ES 2186340 T3 ES2186340 T3 ES 2186340T3 ES 99912439 T ES99912439 T ES 99912439T ES 99912439 T ES99912439 T ES 99912439T ES 2186340 T3 ES2186340 T3 ES 2186340T3
Authority
ES
Spain
Prior art keywords
retinal
retinopathies
polypeptides
fgf
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99912439T
Other languages
English (en)
Inventor
Ivar J Kljavin
Fleur Monique La
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/240,952 external-priority patent/US6331523B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2186340T3 publication Critical patent/ES2186340T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Utilización de un polipéptido activo de FGF-5 en la preparación de un medicamento para retrasar, prevenir o rescatar las células de la retina de la lesión o de la muerte celular.
ES99912439T 1998-03-12 1999-03-10 Utilizacion de polipeptidos fgf-5 para la prevencion de la muerte de neuronas retinales y para el tratamiento de enfermedades oculares. Expired - Lifetime ES2186340T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4138398A 1998-03-12 1998-03-12
US09/240,952 US6331523B1 (en) 1998-03-12 1999-01-29 Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5

Publications (1)

Publication Number Publication Date
ES2186340T3 true ES2186340T3 (es) 2003-05-01

Family

ID=26718088

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99912439T Expired - Lifetime ES2186340T3 (es) 1998-03-12 1999-03-10 Utilizacion de polipeptidos fgf-5 para la prevencion de la muerte de neuronas retinales y para el tratamiento de enfermedades oculares.

Country Status (9)

Country Link
EP (1) EP1061943B1 (es)
JP (2) JP3764047B2 (es)
AT (1) ATE226444T1 (es)
AU (1) AU754380B2 (es)
CA (1) CA2322380C (es)
DE (1) DE69903612T2 (es)
ES (1) ES2186340T3 (es)
IL (1) IL138033A0 (es)
WO (1) WO1999045952A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054813A2 (en) * 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
EP1225909A2 (en) * 1999-10-02 2002-07-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen
EP2292239A3 (en) * 2003-04-18 2011-03-30 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
JP2008064459A (ja) * 2004-12-24 2008-03-21 Univ Kurume 色素上皮由来因子の定量法
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
PT3009449T (pt) 2008-07-16 2018-09-28 Inst Res Biomedicine Anticorpos neutralizantes de citomegalovírus humano e utilização destes
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
WO2015129809A1 (ja) * 2014-02-28 2015-09-03 国立大学法人京都大学 虚血性眼疾患の処置用の医薬組成物
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
JP7095994B2 (ja) 2015-03-02 2022-07-05 アドヴェラム バイオテクノロジーズ， インコーポレイテッド ポリヌクレオチドを網膜錐体に硝子体内送達するための組成物及び方法
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6284194A (en) * 1993-03-12 1994-09-26 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5)
CA2185671A1 (en) * 1994-03-15 1995-09-21 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
US5629284A (en) * 1995-07-24 1997-05-13 Meiji Milk Products Co., Ltd. Method for treating retinal diseases
ATE491029T1 (de) * 1996-10-16 2010-12-15 Zymogenetics Inc Fibroblasten-wachstumsfaktoren-homologe

Also Published As

Publication number Publication date
JP2002526381A (ja) 2002-08-20
DE69903612D1 (de) 2002-11-28
WO1999045952A2 (en) 1999-09-16
CA2322380C (en) 2008-10-14
AU3081399A (en) 1999-09-27
AU754380B2 (en) 2002-11-14
JP2006089489A (ja) 2006-04-06
DE69903612T2 (de) 2003-07-10
JP3764047B2 (ja) 2006-04-05
ATE226444T1 (de) 2002-11-15
EP1061943B1 (en) 2002-10-23
EP1061943A1 (en) 2000-12-27
CA2322380A1 (en) 1999-09-16
IL138033A0 (en) 2001-10-31
WO1999045952A3 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
WO2001009327A3 (en) Method of preventing the injury or death of retinal cells and treating ocular diseases
Fernández-Albarral et al. Glaucoma: from pathogenic mechanisms to retinal glial cell response to damage
IL138033A0 (en) Method of preventing the death of retinal neurons and treating ocular diseases
NO982275D0 (no) FremgangsmÕter for behandling av fotoreseptorer under anvendelse av proteinprodukt av gliacellelinjeavledet neurotrof faktor (GDNF)
WO2021178237A3 (en) Oligonucleotide compositions and methods thereof
WO2020219983A3 (en) Oligonucleotide compositions and methods of use thereof
WO1998004290A3 (en) Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
He et al. Gene expression signatures in tree shrew choroid in response to three myopiagenic conditions
KR890003387A (ko) 국소활성을 갖는 이중-가닥 RMAs조성물
WO2000053760A3 (en) Method of preventing the death of retinal neurons and treating ocular diseases
BR9914207A (pt) Ceto-amidas 2-substituìdas
ITRM20100100A1 (it) Composizione farmaceutica a base di glicirrizina e polimero eg56 per la preparazione di prodotti ad azione flogolitica.
US5629284A (en) Method for treating retinal diseases
EP0083261B1 (fr) Composition thérapeutique, à base d'inosine monophosphaté, pour le traitement des troubles d'accommodation de l'oeil
Bernhard et al. Chronic ulcerating acyclovir-resistant varicella zoster lesions in an AIDS patient
LIMAYE et al. Optic disc hamartoma associated with retinitis pigmentosa
Travers et al. A controlled trial of adenine arabinoside and trifluorothymidine in herpetic keratitis
Møller et al. Early treatment of granular dystrophy (Groenouw type I)
EP1059931A2 (de) Verwendung von cd137 zur förderung der proliferation peripherer monocyten
Shiota Clinical evaluation of acyclovir in the treatment of ulcerative herpetic keratitis
Rotman et al. Two asymptomatic plaques on the chest of a young woman
CA2518676A1 (fr) Utilisation du diazoxide dans le traitement de l'ischemie retinienne
Scopula I Department of Aerospace Medicine, USAF School of Aerospace Medi-I cine, 2513 Kennedy Circle, Brooks AFB, TX 78235-5123 I
NIDES THOMAS, C., CORDIER, J., WATRIN, E.
RU2167667C1 (ru) Гомеопатическое средство для рассасывания помутнений роговицы